News and Trends 4 Nov 2016 Roche hits a Speed Bump on the way to a Hemophilia Cure The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but a safety setback might slow its progress. There is a ‘bloody’ battle in Europe that no one is talking about: who will claim the next Hemophilia blockbuster drug? Roche has established itself as a force to be reckoned with via […] November 4, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2016 This Company has developed a Personalized App to Fight Cancer We say goodbye to the good weather in Spain and cross the Pyrenees to visit Charleroi, an industrial city south of Brussels. There, we find OncoDNA, a young company striving to change the oncology field using DNA. City: Charleroi, Belgium Founded: 2012 Employees: 11 – 50 Financial data: €7.7M raised in September to expand into the global market Mission: […] November 4, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2016 Which Teams are taking home Lego Trophies from iGEM this year? The iGEM 2016 results are in! The world’s largest synthetic biology competition took place in Boston from the 24th to the 31st of October, and European teams took home the grand prizes in two of the three tiers, Postgraduate, Undergraduate and High School. The winners and their projects are listed below. Originally launched by Massachusetts Institute of Technology, […] November 3, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2016 CEVEC is Revolutionizing Industrial Protein & Viral Vector Production CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins. CEVEC is a Biotech with the mission of raising the industrial standard for the large-scale production of glycosylated proteins, viral vaccines and gene therapy […] November 3, 2016 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2016 Antibody Therapies are here to Revolutionize Dermatology Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […] November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2016 Green Waste is Biotech’s New Black Gold: A Review of Biorefineries Replacing petroleum-based products with biobased equivalents is the Holy Grail of the bioeconomy. What are biorefineries doing and how can Biotech help? ‘Biorefinery’ is a buzzword for a cool technological space that draws from GreenTech, Industrial Biotech and SynBio. The core concept behind it is relatively simple: these plants mimic the traditional petroleum refinery, but […] November 2, 2016 - 5 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2016 NHS adopts Next-Gen Sequencing to Test for Birth Defects Despite a lawsuit from Illumina, Premaitha forged ahead with its NGS-based non-invasive prenatal test; the NHS just adopted it as a standard screen. With its seemingly infinite applications, next-generation sequencing (NGS) is a hot area, especially for diagnostics biotechs. A number have been founded in recent years to develop prenatal tests for birth defects, and […] November 2, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2016 Novo Nordisk pressured into Dropping Needle-Free Oral Insulin Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […] November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2016 This Technology could Open Up a new 4th Generation of Therapeutic Antibodies From everyday immunostaining to billion-euro therapies, antibodies have become essential in Biotech. Selecting the right antibodies that are as close to human as possible minimizes risks and can be the key to success, especially in medical applications. What goes into making the best therapeutic antibodies? To answer this question, we sat down with BIOTEM, an experienced provider of custom […] November 1, 2016 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2016 The Toilet has been Reinvented: Now it is Waterless! About 1,400 children under 5 die of sanitation-related illnesses daily. The Cranfield Water Science Institute and the Gates Foundation may have a solution: a waterless toilet. Lack of access to clean water and proper sanitation is the main issue in third-world and developing countries, causing health issues and drinking water contamination. Over 2.4 billion people […] November 1, 2016 - 5 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 Shooting for the Moon: German Biotech Acquired for a Record €1.3B Ganymed Pharmaceuticals is the protagonist of Germany’s biggest biotech deal ever; Astellas Pharma has offered up to €1.3B to get hold of Ganymed’s first-in-class cancer antibody technology. Ganymed Pharmaceuticals develops first-in-class antibody therapies for cancer. Its technology seems to be so promising that the Japanese Astellas Pharma has decided to acquire it in what will be the […] October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 This might be the First 3-in-1 Therapy for Highly Metastatic Cancer Amcure’s candidate for highly metastatic epithelial cancers is about to start clinical trials. The compound can shut down three oncological pathways simultaneously through a single molecular target. Amcure is a spin-off from the Karlsruhe Institute of Technology in Germany, established in 2012. The company develops treatments for highly metastatic forms of cancer using peptide-based compounds targeting angiogenesis. It […] October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email